Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
US8039595B2 · kind B2 · utility
8Cited by
73References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2009 |
| Grant date | Oct 18, 2011 |
| Priority date | — |
| Expiry date | Feb 26, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.